Lonza and Agennix have made a tactical alliance over the Phase III production of a non-small cell lung cancer therapy in the hopes it will improve the chance of joint manufacturing after the commerical launch.
in-PharmaTechnologist brings you a round-up of the latest new facilities and expansions for drugsmakers, including added cytotoxic capabilities for BTL, Jubilant’s launch of a special economic zone in India and plans for a $20m API plant for Omkar.
Pharmas and biopharmas should adopt a “nimble”, more flexible approach when building relationships with CROs to stay ahead of the changing market, according to a new report.
Acquisition by private equity group Genstar Capital would allow eResearch Technologies (ERT) a more flexible approach and reduce costs according to CEO Jeff Litwin.
A new filtration cartridge supply deal between GE Healthcare and Refine Technologies is a further indication of Biopharma’s desire for greater connectivity between processing techs.
Outsourcing-Pharma presents its weekly round-up of the latest changes on the pharmaceutical jobs ladder including news from Lonza, Agilux and Chiltern.
in-PharmaTechnologist presents its weekly round-up of the latest appointments within the pharmaceutical industry including news from Raptor, Cangene and Merck & Co.
Affymetrix will distribute a mircoarray developed by Almac for personalised medicine development applications under an exclusive global distribution deal.
Outsourcing-Pharma presents its weekly round-up of the latest appointments within the pharmaceutical industry, including news from AMRI, AIT Laboratories, and Chemgen.
Laboratory services firm Warnex has put back the release of its full year results and received a formal notice of default from the holder of its outstanding debentures.
INC Research says the closure of former Kendle office in Connecticut will better balance resources and that – where possible – staff will be reassigned.
Contract services firm Warnex says its analytical and bioanalytical divisions have attracted ‘interest’ from buyers that would exceed its current market cap.
New research suggests that – in general - strategic partnerships are working but CROs still need to improve on sponsors’ ‘high priority’ objectives or risk losing deals.
in-PharmaTechnologist present its weekly round-up of the latest appointments within the pharmaceutical industry, including news from Delcath, Genesis and Intarcia.
